1-2 of 2
Alexander Myasnikov, MD PhD
Close
Sort by
Journal Articles

A Drug-Drug Interaction Study of Ibrutinib with Moderate and Strong CYP3A Inhibitors in Patients with B-Cell Malignancy

Jan de Jong, PhD, Peter Hellemans, MD, Severijn De Wilde, Daniel Patricia, Tara Masterson, Georgii Manikhas, MD PhD, Alexander Myasnikov, MD PhD, Dzhelil Osmanov, MD, Raul Cordoba, MD PhD, Carlos Panizo, Loeckie de Zwart, PhD, Jan Snoeys, PhD, Vijay Chauhan, PhD, James Jiao, PhD, Juthamas Sukbuntherng, PhD, Daniele Ouellet, PhD
Journal: Blood
Blood (2016) 128 (22): 3964.
https://doi.org/10.1182/blood.V128.22.3964.3964
Published: 2016
Journal Articles

Key Results of International Randomized Open-Label Clinical Study of BCD-020 (rituximab biosimilar candidate) in Patients with B-Cell Non-Hodgkin’s Lymphoma

Kamil Kaplanov, Andrey Zaritskiy, MD, Sergey Alexeev, MD, PhD, Elena Volodicheva, Alexander Loginov, MD, Rashida Orlova, MD, PhD, Victoria Dvornichenko, MD, PhD, Marina Kosinova, MD, Olga Serduk, Vladimir Milovanov, MD, Alexander Myasnikov, MD PhD, Shekar Patil, MD, Shekar Patil, MD, Bharath Rangarajan, MD, Senthil Jagannathan Rajappa, MD DM, Minish Jain, MD, Sharanabasappa Nirni, MD, PhD, Akhil Deka, M, Grigoriy B Rekhtman, Iryna Kryachok, Zvenyslava Maslyak, Ekaterina Chernyaeva, MD, Roman Ivanov, MD, PhD, Alexander Isaev, MD
Journal: Blood
Blood (2014) 124 (21): 5467.
https://doi.org/10.1182/blood.V124.21.5467.5467
Published: 2014